US20170239218A1 - Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof - Google Patents

Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof Download PDF

Info

Publication number
US20170239218A1
US20170239218A1 US15/441,297 US201715441297A US2017239218A1 US 20170239218 A1 US20170239218 A1 US 20170239218A1 US 201715441297 A US201715441297 A US 201715441297A US 2017239218 A1 US2017239218 A1 US 2017239218A1
Authority
US
United States
Prior art keywords
pharmaceutically acceptable
optionally
formula
long
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/441,297
Other languages
English (en)
Inventor
Loic Patrick Le Hir de Fallois
Charles Q. Meng
Susan Mancini Cady
Peter Cheifetz
Izabela Galeska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Priority to US15/441,297 priority Critical patent/US20170239218A1/en
Assigned to MERIAL, INC. reassignment MERIAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CADY, SUSAN MANCINI, CHEIFETZ, Peter, GALESKA, IZABELA, LE HIR DE FALLOIS, LOIC PATRICK, MENG, CHARLES Q.
Publication of US20170239218A1 publication Critical patent/US20170239218A1/en
Priority to US16/534,912 priority patent/US11497732B2/en
Assigned to Boehringer Ingelheim Animal Health USA Inc. reassignment Boehringer Ingelheim Animal Health USA Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MERIAL, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
    • A01N55/08—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing boron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention provides pesticidal and antiparasitic isoxazoline compounds, and long-acting injectable compositions comprising at least one isoxazoline active agent, a liquid polyethylene glycol (PEG) and, optionally, a co-solvent.
  • the invention also provides for the use of these compounds and compositions against pests and parasites (including ectoparasites (e.g., fleas or ticks) and/or endoparasites), and methods for controlling pests and preventing or treating parasitic infections and infestations in animals.
  • ectoparasites such as fleas, ticks and parasitic flies
  • endoparasites such as nematodes and other worms.
  • domesticated animals such as cats and dogs, are often infested with one or more of the following ectoparasites:
  • Fleas are a particular problem because not only do they adversely affect the health of the animal or human, but they also cause a great deal of psychological stress. Moreover, fleas may also transmit pathogenic agents to animals and humans, such as tapeworm ( Dipylidium caninum ).
  • ticks are also harmful to the physical and psychological health of the animal or human.
  • Major diseases which may be transmitted by ticks include borreliosis (Lyme disease caused by Borrelia burgdorferi ), babesiosis (or piroplasmosis caused by Babesia spp.) and rickettsioses (e.g. Rocky Mountain spotted fever).
  • Ticks also release toxins which cause inflammation or paralysis in the host. Occasionally, these toxins are fatal to the host.
  • farm animals are also susceptible to parasite infestations.
  • cattle and other bovines are affected by a large number of parasites.
  • a parasite which is prevalent among cattle in some regions are ticks of the genus Rhipicephalus , especially those of the species microplus (cattle tick), decoloratus and annulatus .
  • Ticks such as Rhipicephalus microplus are difficult to control because they lay eggs in the pasture where farm animals graze.
  • This species of ticks is considered a one-host tick and spends immature and adult stages on one animal before the female engorges and falls off the host to lay eggs in the environment. The life cycle of the tick is approximately three to four weeks.
  • Rhipicephalus microplus may infest buffalo, horses, donkeys, goats, sheep, deer, pigs, and dogs.
  • a heavy tick burden on animals can decrease production and damage hides as well as transmit diseases such as babesiosis (“cattle fever”) and anaplasmosis.
  • helminthiasis which is caused by of parasitic worms categorized as cestodes (tapeworm), nematodes (roundworm) and trematodes (flatworm or flukes).
  • cestodes tapeworm
  • nematodes roundworm
  • trematodes flatworm or flukes
  • parasites which occur in the gastrointestinal tract of animals and humans include those from the genus Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Toxocara, Toxascaris, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filarial worms and the extra intestinal stages of Strongyloides, Toxocara and Trichinella.
  • isoxazole and isoxazoline-containing compounds have been demonstrated to be effective against parasites that harm animals.
  • U.S. Pat. No. 7,964,204 discloses isoxazoline compounds according to formula (I) below, which are active against ectoparasites and/or endoparasites.
  • WO 2013/039948 A1 provides for topical veterinary compositions comprising at least one isoxazoline active agent and WO 2013/119442 A1 provides for oral veterinary compositions such as a soft chew which comprising at least one isoxazoline active agent.
  • active agents in additional to topical and oral dosage forms, it is sometimes possible to formulate active agents as long-acting compositions, depending upon, for example, the physiochemical properties of the individual active agent; these properties include, for example, solubility, bioavailability, etc.
  • a bioactive substance such as, for example, an avermectin or a milbemycin and a biological acceptable polymer.
  • the present invention provides for novel and inventive long-acting injectable compositions for the treatment or prevention of parasite infections or infestations in an animal comprising an antiparasitic effective amount of at least one isoxazoline compound, a liquid PEG and/or a pharmaceutically acceptable neutral oil, optionally, a co-solvent and optionally a pharmaceutically acceptable additive or excipient.
  • the inventive long-acting compositions generally show desirable bioavailability and duration of efficacy, while causing minimal irritation at the injection site.
  • the compositions also provide desirable safety profiles toward the warm-blooded and bird animal recipients.
  • a single administration of such compositions generally provides potent activity against one or more parasites (e.g., ectoparasites), while also tending to provide fast onset of activity, long duration of activity, and/or desirable safety profiles.
  • the invention encompasses uses or veterinary uses of the isoxazoline compounds and compositions described herein for the treatment or prevention of parasitic infections and infestations in or on animals (either wild or domesticated), including livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle, with the aim of ridding these hosts of parasites commonly encountered by such animals.
  • the compounds of formula (Id) described herein are useful for protecting crops, plants, plant propagation material, or material containing wood or derived from wood, from harmful pests.
  • the invention also provides methods for the treatment or prevention of parasitic infections and infestations in animals, comprising administering an effective amount of long-acting injectable compositions comprising an antiparasitic effective amount of at least one isoxazoline compound together with at least one liquid PEG and/or a pharmaceutically acceptable neutral oil and optionally a co-solvent, a pharmaceutically acceptable additive and/or excipient, wherein the composition does not contain a pharmaceutically acceptable biodegradable polymer as defined herein.
  • inventive isoxazoline-containing compositions described herein exhibit superior broad spectrum efficacy against harmful parasites (e.g. ectoparasites such as fleas and ticks) more rapidly, and over a long duration compared to other injectable compositions containing isoxazoline active agents known in the art while exhibiting minimal irritation at the injection site.
  • This invention also provides for the use of an isoxazoline in the preparation of a long-acting injectable composition for the treatment or prevention of an animal against parasites.
  • the invention provides for long-acting injectable compositions comprising antiparasitic effective amounts of at least one isoxazoline of formula (I) below, in combination and a pharmaceutically or veterinary acceptable liquid carrier, where variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , B 1 , B 2 , B 3 , R 1 , R 2 , R 4 , R 5 , W and n are defined herein.
  • the invention provides long-acting injectable compositions comprising an isoxazoline compound of formula (Ic):
  • compositions comprising a compound of formula (Ic) wherein X 1 is chloro, X 2 is fluoro and X 3 is CF 3 have been shown to have surprisingly long-lasting and excellent efficacy against Rhipicephalus microplus with a quick onset and a very long duration of time.
  • the long-acting injectable compositions and methods comprise 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide as the active agent.
  • the long-acting injectable compositions may further comprise one or more additional active agents that are systemically active.
  • Systemically-acting active agents may include, but are not limited to, isoxazoline active agents of different structure, a systemically-acting neonicotinoid active agent, a systemically-acting 1-N-arylpyrazole active agent, macrocyclic lactones such as avermectin and milbemycin compounds, a cyclic depsipeptide such as emodepside or PF1022A or analogs thereof, benzimidazoles, imidazothiazoles, a tetrahydropyrimidine active agent, an organophosphate active agent, levamisole, a paraherquamide active agent and/or a marcfortine active agent, praziquantel, closantel, clorsulon, morantel, pyrantel, a spinosyn or spinosoid active agent, an amino acetonitrile active
  • the long-acting injectable compositions comprise at least one macrocyclic lactone active agent, including, but not limited to, avermectins or milbemycins.
  • the avermectin or milbemycin active agent is eprinomectin, ivermectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, or moxidectin.
  • compositions and methods comprise at least one of thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an aryloazol-2-yl cyanoethylamino active agent.
  • the invention provides novel and inventive pesticidal and parasiticidal isoxazoline compounds of formula (Id) shown:
  • X 1 is bromo, chloro, iodo or fluoro
  • X 2 is chloro, fluoro or CF 3
  • Y is a group Y-1, Y-2, Y-3, Y-4 where Z is N or CH, Y-5 or Y-6
  • Q is OH, —C(O)NHCH 2 C(O)NHCH 2 CF 3 , —C(O)CH 2 S(O) 2 CH 3 , —C(O)NHCH 2 CH 2 SCH 3 or (—CH 2 —)(—CH 2 —)N(CO)CH 2 S(O) 2 CH 3 .
  • the compounds of formula (Id) are highly active against arthropod pests and parasites and useful for protecting animals, including livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle, from parasites that infest or infect such animals.
  • livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle, from parasites that infest or infect such animals.
  • the invention also provides pesticidal isoxazoline compounds of formula (Id) for protecting crops, plants, plant propagation material, or material containing wood or derived from wood, from harmful pests.
  • the present invention provides for novel and inventive long-acting injectable compositions for the treatment or prevention of parasitic infections or infestations in an animal comprising an antiparasitic effective amount of at least one isoxazoline compound, a liquid PEG and/or a pharmaceutically acceptable neutral oil, and optionally a co-solvent, a pharmaceutically acceptable additive and/or excipient, wherein no other pharmaceutically acceptable polymers, as defined herein are present.
  • the present invention provides for long-acting injectable compositions for the treatment and/or prophylaxis of parasitic infections and infestations in or on animals comprising an antiparasitic effective amount of at least one isoxazoline compound and an effective amount of at least one additional active agent, a PEG and/or a pharmaceutically acceptable neutral oil and, optionally, a co-solvent, a pharmaceutically acceptable additive and/or excipient.
  • the present invention provides for a long-acting injectable composition for the treatment and/or prophylaxis of parasitic infections and infestations in or on animals comprising:
  • an antiparasitic effective amount of at least one isoxazoline active agent which is:
  • a 1 , A 2 , A 3 , A 4 , A 5 and A 6 are independently selected from the group consisting of CR 3 and N, provided that at most 3 of A 1 , A 2 , A 3 , A 4 , A 5 and A 6 are N;
  • B 1 , B 2 and B 3 are independently selected from the group consisting of CR 2 and N;
  • W is O or S
  • R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R 6 ;
  • each R 2 is independently H, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 haloalkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 haloalkylsulfinyl, C, —C 6 alkylsulfonyl, C 1 -C 6 haloalkylsulfonyl, C 1 -C 6 alkylamino, C 2 -C 6 dialkylamino, C 2 -C 4 alkoxycarbonyl, —CN or —NO 2 ;
  • each R 3 is independently H, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 haloalkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 haloalkylsulfonyl, C 1 -C 6 alkylamino, C 2 -C 6 dialkylamino, —CN or —NO 2 ;
  • R 4 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl, C 4 -C 7 cycloalkylalkyl, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl;
  • R 5 is H, OR 10 , NR 11 R 12 or Q 1 ; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R 7 ; or
  • R 4 and R 5 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C 1 -C 2 alkyl, halogen, —CN, —NO 2 and C 1 -C 2 alkoxy; each R 6 is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, —CN or —NO 2 ;
  • each R 7 is independently halogen; C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylamino, C 2 -C 8 dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 7 alkylcarbonyl, C 2 -C 7 alkoxycarbonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylcarbonyl, C 2 -C 7 haloalkoxycarbonyl, C 2 -C 7 haloalkylaminocarbonyl, C 3 -C 9 dihaloalkylaminocarbonyl, hydroxy, —
  • each R 8 is independently halogen, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 haloalkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 haloalkylsulfonyl, C 1 -C 6 alkylamino, C 2 -C 6 dialkylamino, C 2 -C 4 alkoxycarbonyl, —CN or NO 2 ;
  • each R 9 is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 haloalkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 haloalkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 haloalkylsulfonyl, C 1 -C 6 alkylamino, C 2 -C 6 dialkylamino, —CN, —NO 2 , phenyl or pyridinyl;
  • R 10 is H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with one of more halogen;
  • R 11 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl, C 4 -C 7 cycloalkylalkyl, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl;
  • R 12 is H; Q 3 ; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R 7 ; or
  • R 11 and R 12 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C 1 -C 2 alkyl, halogen, —CN, —NO 2 and C 1 -C 2 alkoxy;
  • Q 1 is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or 10-membered fused bicyclic ring system optionally containing one to three heteroatoms selected from up to 1 O, up to 1 S and up to 3 N, each ring or ring system optionally substituted with one or more substituents independently selected from R 8 ;
  • each Q 2 is independently a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R 9 ;
  • Q 3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R 9 ;
  • n 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and/or
  • R 1 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each which is unsubstituted or substituted with one or more of halogen, hydroxy, amino, alkyl- or di(alkyl)amino, alkyl, cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, R 7 S(O)—, R 7 S(O) 2 —, R 7 C(O)—, R 7 R 8 NC(O)—, R 7 OC(O)—, R 7 C(O)O—, R 7 C(O)NR 8 —
  • X is aryl or heteroaryl, which may be unsubstituted or substituted by one or more of halogen, hydroxy, amino, alkyl- or di(alkyl)amino, alkyl, cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, R 7 S(O)—, R 7 S(O) 2 —, R 7 C(O)—, R 7 R 8 NC(O)—, R 7 OC(O)—, R 7 C(O)O—, R 7 C(O)NR 8 —, —CN or —NO 2 ;
  • a 1 is oxygen
  • a 2 is oxygen, NR 2 or CR 7 R 8 ;
  • G is G-1 or G-2;
  • B 1 , B 2 , B 3 , B 4 and B 5 are independently N or C—R 9 ;
  • Y is hydrogen, halogen, —CN; or Y is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, aryl, or heterocyclyl or heteroaryl each of which is unsubstituted or substituted with one or more of halogen, hydroxy, amino, alkyl- or di(alkyl)amino, alkyl, cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, R 7 S(O)—, R 7 S(O) 2 —, R 7 C(O)—, R 7 R 8 NC(O)—, R 7 OC(O)—,
  • R 2 , R 3 are independently hydrogen, alkyl, haloalkyl, thioalkyl, alkylthioalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, R 10 S(O)—, R 10 S(O) 2 —, R 10 C(O)—, R 10 C(S)—, R 10 R 11 NC(O)—, R 10 R 11 NC(S)—R 10 OC(O)—;
  • R 4 , R 5 and R 6 are independently hydrogen, alkyl, haloalkyl, thioalkyl, alkylthioalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, aryl or heteroaryl;
  • R 7 and R 8 are independently hydrogen, alkyl, haloalkyl, thioalkyl, alkylthioalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, haloalkenyl, alkynyl or haloalkynyl;
  • R 9 is hydrogen, halogen, —CN, or alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each which is unsubstituted or substituted with one or more of halogen, hydroxy, amino, alkyl- or di(alkyl)amino, alkyl, cycloalkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, R 7 S(O)—, R 7 S(O) 2 —, R 7 C(O)—, R 7 R 8 NC(O)—, R 7 OC(O)—, R 7 C(O)O—
  • R 10 , R 11 , R 12 and R 13 are each independently hydrogen, alkyl, haloalkyl, thioalkyl, alkylthioalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, haloalkenyl, alkynyl or haloalkynyl; or
  • R 10 together with R 11 form ⁇ O, ⁇ S or ⁇ NR 2 ;
  • R 12 together with R 13 form ⁇ O, ⁇ S or ⁇ NR 2 ;
  • W is O, S or NR 2 ;
  • n 1-4;
  • n 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and/or
  • R 1 , R 2 and R 3 are independently H, Cl, F or CF 3 ;
  • Y is the diradical group
  • T is a C 1 -C 6 -alkyl group which is unsubstituted or substituted by halogen, cyano, nitro, amino, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylthio, C 1 -C 6 -alkylthio, carboxy, carbamoyl or C 2 -C 6 -alkanoyl group which may be unsubstituted or substituted in the alkyl portion by halogen or a pharmaceutical acceptable salt thereof; and/or
  • Y is hydrogen, fluoro, chloro or bromo
  • R 3a and R 3b are independently selected from hydrogen, methyl, ethyl or fluoromethyl; or R 3a and R 3b together combine with the carbon to which they are attached to form a cyclopentyl ring or a cyclohexyl ring; or a pharmaceutically acceptable salt thereof;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prophylaxis of parasitic infections and infestations in or on animals comprising:
  • an antiparasitic effective amount of at least one isoxazoline active agent which is:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prophylaxis of parasitic infections and infestations in or on animals comprising:
  • an antiparasitic effective amount of at least one isoxazoline active agent which is:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prophylaxis of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • R 2 independently is halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl
  • R 4 is H or C 1 -C 6 alkyl
  • R 5 is C 1 -C 4 alkyl optionally substituted with one or more R 7 ; and R 7 is C 2 -C 7 alkylcarbonyl, C 2 -C 7 alkoxycarbonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylcarbonyl, C 2 -C 7 haloalkoxycarbonyl, C 2 -C 7 haloalkylaminocarbonyl, C 3 -C 9 dihaloalkylaminocarbonyl (e.g., —CH 2 C(O)NHCH 2 CF 3 ); and
  • n 0, 1 or 2;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is not miscible with water or only partially soluble in water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812),
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812),
  • C 8 -C 10 triglycerides combined with linoleic acid e.g. MIGLYOL® 818
  • C 8 -C 10 triglycerides combined with succinic acid e.g. MIGLYOL® 829
  • propylene glycol diester of C 8 -C 10 fatty acids e.g. MIGLYOL® 840
  • castor oil cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is not miscible with water or only partially soluble in water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the long-acting injectable compositions of present invention comprise an antiparasitic effective amount of at least one isoxazoline of formula (Ib), which has the formula:
  • R 2 independently is halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl
  • R 4 is H or C 1 -C 6 alkyl
  • R 5 is C 1 -C 4 alkyl optionally substituted with one or more R 7 ; and R 7 is C 2 -C 7 alkylcarbonyl, C 2 -C 7 alkoxycarbonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylcarbonyl, C 2 -C 7 haloalkoxycarbonyl, C 2 -C 7 haloalkylaminocarbonyl, C 3 -C 9 dihaloalkylaminocarbonyl (e.g., —CH 2 C(O)NHCH 2 CF 3 ); and
  • n 0, 1 or 2.
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each independently H, halogen, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the long-acting injectable compositions of the invention comprise a compound of formula (Ic) wherein X 1 and X 3 are independently halogen and X 2 is hydrogen.
  • the long-acting injectable compositions of the invention comprise a compound of formula (Ic), wherein X 1 , X 2 and X 3 are each independently halogen.
  • the long-acting injectable compositions comprise a compound of formula (Ic), wherein X 1 and X 3 are each independently halogen and X 2 is C 1 -C 3 haloalkyl.
  • the invention provides a long-acting injectable composition
  • a long-acting injectable composition comprising a compound of formula (Ic), wherein X 1 and X 2 are independently halogen and X 3 is C 1 -C 3 haloalkyl.
  • the invention provides a long-acting injectable composition
  • a long-acting injectable composition comprising a compound of formula (Ic), wherein X 1 and X 2 are independently halogen and X 3 is
  • the invention provides a long-acting injectable composition
  • a compound of formula (Ic) wherein X 1 and X 3 are chloro and X 2 is hydrogen.
  • the invention provides a long-acting injectable composition
  • a compound of formula (Ic) wherein X 1 is chloro, X 2 is fluoro and X 3 is CF 3 .
  • the invention provides a long-acting injectable composition
  • a long-acting injectable composition comprising a compound of formula (Ic), wherein X 1 and X 3 are chloro and X 2 is fluoro.
  • the long-acting injectable compositions of present invention comprise an antiparasitic effective amount of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalanecarboxamide (Compound of formula Ia).
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are each independently halogen or C 1 -C 3 haloalkyl
  • X 2 is halogen or hydrogen
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are each independently halogen or C 1 -C 3 haloalkyl
  • X 2 is halogen or hydrogen
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are each independently halogen or C 1 -C 3 haloalkyl
  • X 2 is halogen or hydrogen
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro
  • X 3 is chloro or CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro
  • X 3 is chloro or CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent that is miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro
  • X 3 is chloro or CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro
  • X 3 is chloro or CF 3 ;
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro
  • X 3 is chloro or CF 3 ;
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro
  • X 3 is chloro or CF 3 ;
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 2 are each independently chloro or fluoro; and X 3 is chloro or CF 3 ;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are each chloro
  • X 2 is fluoro or hydrogen
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are each chloro
  • X 2 is fluoro or hydrogen
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent that is miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are each chloro
  • X 2 is fluoro or hydrogen
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent that is miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent is a C 1 -C 6 alcohol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 is chloro
  • X 2 is fluoro
  • X 3 is CF 3 ;
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent that is miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • co-solvent is a C 8 -C 10 triglyceride, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 and X 3 are chloro
  • X 2 is fluoro
  • co-solvent optionally, at least one co-solvent wherein said co-solvent is ethanol, isopropanol, benzyl alcohol, or a combination thereof;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each chloro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each chloro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent that is miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each chloro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each chloro
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • a co-solvent wherein the co-solvent is a C 1 -C 6 alcohol, a glycol ether (e.g., including, but limited to, diethyleneglycol monoethyl ether, butyl diglycol, dipropylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like), glycerol, propylene glycol, cyclic carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethylsulfoxide or glycerol formal, or a combination thereof;
  • a glycol ether e.g., including, but limited to, diethyleneglycol monoethyl ether, buty
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each chloro
  • a co-solvent optionally, a co-solvent, wherein the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids, C 8 -C 10 triglycerides (e.g. MIGLYOL® 810 and MIGLYOL® 812), C 8 -C 10 triglycerides combined with linoleic acid (e.g. MIGLYOL® 818), C 8 -C 10 triglycerides combined with succinic acid (e.g. MIGLYOL® 829), propylene glycol diester of C 8 -C 10 fatty acids (e.g. MIGLYOL® 840), castor oil, cottonseed oil, sesame oil, soybean oil and safflower oil, or a combination thereof;
  • the co-solvent is benzyl alcohol, benzyl benzoate, ethyl acetate, triacetin, lipids,
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each chloro
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each independently chloro or fluoro;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:
  • X 1 , X 2 and X 3 are each independently chloro or fluoro;
  • At least one pharmaceutically acceptable polymer which is a liquid PEG and/or a pharmaceutically acceptable neutral oil
  • co-solvent optionally, at least one co-solvent, wherein said co-solvent is a polar solvent that is miscible with water;
  • the present invention provides for a long-acting injectable composition for the treatment and/or prevention (prophylaxis) of parasitic infections and infestations in or on animals comprising:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Toxicology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/441,297 2016-02-24 2017-02-24 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof Abandoned US20170239218A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/441,297 US20170239218A1 (en) 2016-02-24 2017-02-24 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
US16/534,912 US11497732B2 (en) 2016-02-24 2019-08-07 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299333P 2016-02-24 2016-02-24
US201662379348P 2016-08-25 2016-08-25
US15/441,297 US20170239218A1 (en) 2016-02-24 2017-02-24 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/534,912 Division US11497732B2 (en) 2016-02-24 2019-08-07 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Publications (1)

Publication Number Publication Date
US20170239218A1 true US20170239218A1 (en) 2017-08-24

Family

ID=58231773

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/441,297 Abandoned US20170239218A1 (en) 2016-02-24 2017-02-24 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
US16/534,912 Active 2037-11-28 US11497732B2 (en) 2016-02-24 2019-08-07 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/534,912 Active 2037-11-28 US11497732B2 (en) 2016-02-24 2019-08-07 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Country Status (29)

Country Link
US (2) US20170239218A1 (fr)
EP (2) EP3419424B1 (fr)
JP (2) JP7110106B2 (fr)
KR (1) KR20180113614A (fr)
CN (2) CN109068651B (fr)
AU (4) AU2017223828B2 (fr)
BR (1) BR112018017265B1 (fr)
CA (1) CA3015357A1 (fr)
CL (1) CL2018002402A1 (fr)
CO (1) CO2018008829A2 (fr)
CY (1) CY1124287T1 (fr)
DK (1) DK3419424T3 (fr)
EA (1) EA036716B1 (fr)
ES (1) ES2892078T3 (fr)
HK (1) HK1257959A1 (fr)
HR (1) HRP20211042T1 (fr)
HU (1) HUE054931T2 (fr)
IL (2) IL261197B (fr)
LT (1) LT3419424T (fr)
MX (2) MX2018010160A (fr)
NZ (1) NZ745859A (fr)
PL (1) PL3419424T3 (fr)
PT (1) PT3419424T (fr)
SG (2) SG10202007581QA (fr)
SI (1) SI3419424T1 (fr)
TW (3) TWI801959B (fr)
UY (1) UY37137A (fr)
WO (1) WO2017147352A1 (fr)
ZA (1) ZA201805476B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018194144A1 (fr) * 2017-04-19 2018-10-25 三井化学アグロ株式会社 Composition de conservation du bois et procédé de traitement de conservation du bois
WO2019091936A1 (fr) 2017-11-07 2019-05-16 Intervet International B.V. Compositions pharmaceutiques à base d'isoxazoline injectables et leur utilisation contre l'infestation par des parasites
CN111655241A (zh) * 2017-12-15 2020-09-11 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
WO2020225143A1 (fr) 2019-05-03 2020-11-12 Intervet International B.V. Compositions pharmaceutiques injectables et leurs utilisations
WO2021122515A1 (fr) * 2019-12-16 2021-06-24 Intervet International B.V. Lutte contre les parasites chez les ruminants
WO2021233967A1 (fr) 2020-05-20 2021-11-25 Intervet International B.V. Compositions pharmaceutiques injectables et leurs utilisations
US11858904B2 (en) 2017-11-07 2024-01-02 Intervet Inc. Process for preparing large size isoxazoline particles

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37137A (es) * 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
TWI812673B (zh) * 2018-02-12 2023-08-21 美商富曼西公司 用於防治無脊椎害蟲之萘異噁唑啉化合物
CN113825543A (zh) 2019-03-19 2021-12-21 勃林格殷格翰动物保健美国公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法
WO2021242481A1 (fr) 2020-05-28 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Dispositif de capsule intraruminale à libération bimodale et ses méthodes d'utilisation
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
US20240116854A1 (en) 2021-01-27 2024-04-11 Intervet Inc. Cyclopropylamide compounds against parasites in fish
BR112023015168A2 (pt) 2021-01-27 2023-10-03 Corteva Agriscience Llc Compostos de ciclopropilamida contra parasitas em peixes
CN116253658B (zh) * 2022-11-25 2023-08-11 济南久隆医药科技有限公司 一种阿福拉纳中间体合成方法
CN115959979A (zh) * 2022-12-29 2023-04-14 南京正荣医药化学有限公司 一种3-氯-4-氟-5-三氟甲基三氟苯乙酮的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022089B2 (en) * 2004-03-05 2011-09-20 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060084A (en) 1961-06-09 1962-10-23 Du Pont Improved homogeneous, readily dispersed, pesticidal concentrate
US3299566A (en) 1964-06-01 1967-01-24 Olin Mathieson Water soluble film containing agricultural chemicals
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US4144050A (en) 1969-02-05 1979-03-13 Hoechst Aktiengesellschaft Micro granules for pesticides and process for their manufacture
NL160809C (nl) 1970-05-15 1979-12-17 Duphar Int Res Werkwijze ter bereiding van benzoylureumverbindingen, alsmede werkwijze ter bereiding van insekticide prepara- ten op basis van benzoylureumverbindingen.
JPS4914624A (fr) 1972-06-08 1974-02-08
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US3818047A (en) 1972-08-07 1974-06-18 C Henrick Substituted pyrones
US3920442A (en) 1972-09-18 1975-11-18 Du Pont Water-dispersible pesticide aggregates
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
CH604517A5 (fr) 1976-08-19 1978-09-15 Ciba Geigy Ag
US4172714A (en) 1976-12-20 1979-10-30 E. I. Du Pont De Nemours And Company Dry compactible, swellable herbicidal compositions and pellets produced therefrom
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
US4203976A (en) 1978-08-02 1980-05-20 Merck & Co., Inc. Sugar derivatives of C-076 compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS57139012A (en) 1981-02-23 1982-08-27 Sankyo Co Ltd Anthelmintic composition
GB2095558B (en) 1981-03-30 1984-10-24 Avon Packers Ltd Formulation of agricultural chemicals
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
DE3235931A1 (de) 1982-09-29 1984-03-29 Bayer Ag, 5090 Leverkusen Koeder zur bekaempfung von ungeziefer
JPS59199673A (ja) 1983-04-25 1984-11-12 Sumitomo Chem Co Ltd 含窒素複素環化合物、その製造法およびそれを有効成分とする有害生物防除剤
BR8404834A (pt) 1983-09-26 1985-08-13 Agrigenetics Res Ass Metodo para modificar geneticamente uma celula vegetal
US5304732A (en) 1984-03-06 1994-04-19 Mgi Pharma, Inc. Herbicide resistance in plants
IL76708A (en) 1984-10-18 1990-01-18 Ciba Geigy Ag Substituted n-benzoyl-n'-(2,5-dichloro-4(1,1,2,3,3,3-hexafluoropropyloxy)-phenyl)ureas,their preparation and pesticidal compositions containing them
BR8600161A (pt) 1985-01-18 1986-09-23 Plant Genetic Systems Nv Gene quimerico,vetores de plasmidio hibrido,intermediario,processo para controlar insetos em agricultura ou horticultura,composicao inseticida,processo para transformar celulas de plantas para expressar uma toxina de polipeptideo produzida por bacillus thuringiensis,planta,semente de planta,cultura de celulas e plasmidio
ATE67493T1 (de) 1985-02-04 1991-10-15 Bayer Agrochem Kk Heterocyclische verbindungen.
EP0237482A1 (fr) 1986-03-06 1987-09-16 Ciba-Geigy Ag Dérivés de la C(29)-carbonyloxy-milbémycine pour la lutte contre les parasites d'espèces végétales ou animales
ATE57390T1 (de) 1986-03-11 1990-10-15 Plant Genetic Systems Nv Durch gentechnologie erhaltene und gegen glutaminsynthetase-inhibitoren resistente pflanzenzellen.
BR8701302A (pt) 1986-03-25 1987-12-22 Sankyo Co Compostos macrolideos,sua preparacao e seu uso
ES2039258T3 (es) 1986-07-02 1993-09-16 Ciba-Geigy Ag Pesticidas.
US5013659A (en) 1987-07-27 1991-05-07 E. I. Du Pont De Nemours And Company Nucleic acid fragment encoding herbicide resistant plant acetolactate synthase
IL83348A (en) 1986-08-26 1995-12-08 Du Pont Nucleic acid fragment encoding herbicide resistant plant acetolactate synthase
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
EP0319142B1 (fr) 1987-11-03 1994-04-06 Beecham Group Plc Intermédiaires pour la preparation des antibiotiques macrolides à activité anthelmintique
FR2629098B1 (fr) 1988-03-23 1990-08-10 Rhone Poulenc Agrochimie Gene chimerique de resistance herbicide
KR900003088B1 (ko) 1988-03-26 1990-05-07 재단법인 한국화학연구소 5-하이드록시피라졸 유도체
US5180587A (en) 1988-06-28 1993-01-19 E. I. Du Pont De Nemours And Company Tablet formulations of pesticides
CA2005658A1 (fr) 1988-12-19 1990-06-19 Eliahu Zlotkin Toxines insecticides; genes renfermant le code de ces toxines; anticorps fixes a elles; cellules vegetales et plantes mutantes exprimant ces toxines
NZ232422A (en) 1989-02-16 1992-11-25 Merck & Co Inc 13-ketal milbemycin derivatives and parasiticides
ES2199931T3 (es) 1989-03-24 2004-03-01 Syngenta Participations Ag Plantas transgenicas resistentes a enfermedades.
DK0415688T3 (da) 1989-08-30 1999-08-23 Aeci Ltd Fremgangsmåde til fremstilling af et doseringssystem samt fremgangsmåde til behandling af en genstand eller et locus
ES2074547T3 (es) 1989-11-07 1995-09-16 Pioneer Hi Bred Int Lectinas larvicidas, y resistencia inducida de las plantas a los insectos.
IE904606A1 (en) 1989-12-21 1991-07-03 Beecham Group Plc Novel products
ES2065680T3 (es) 1990-03-12 1995-02-16 Du Pont Granulos de plaguicida dispersables en agua o solubles en agua a partir de aglutinantes activados por calor.
ATE241007T1 (de) 1990-03-16 2003-06-15 Calgene Llc Dnas, die für pflanzliche desaturasen kodieren und deren anwendungen
JP3325022B2 (ja) 1990-06-18 2002-09-17 モンサント カンパニー 植物中の増加された澱粉含量
DE69132939T2 (de) 1990-06-25 2002-11-14 Monsanto Technology Llc Glyphosattolerante pflanzen
EP0480679B1 (fr) 1990-10-11 1996-09-18 Sumitomo Chemical Company Limited Composition pesticide
SE467358B (sv) 1990-12-21 1992-07-06 Amylogene Hb Genteknisk foeraendring av potatis foer bildning av staerkelse av amylopektintyp
NZ247278A (en) 1991-02-12 1995-03-28 Ancare Distributors Veterinary anthelmintic drench comprising a suspension of praziquantel in a liquid carrier
DE4104782B4 (de) 1991-02-13 2006-05-11 Bayer Cropscience Gmbh Neue Plasmide, enthaltend DNA-Sequenzen, die Veränderungen der Karbohydratkonzentration und Karbohydratzusammensetzung in Pflanzen hervorrufen, sowie Pflanzen und Pflanzenzellen enthaltend dieses Plasmide
WO1992022555A1 (fr) 1991-06-17 1992-12-23 Beecham Group Plc Derives de paraherquamide, precurseur de ces derives, procedes de preparation, microorganisme utilise et utilisation de ces derives comme agents parasiticides
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US5345377A (en) 1992-10-30 1994-09-06 Electric Power Research Institute, Inc. Harmonic controller for an active power line conditioner
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
DE4322211A1 (de) 1993-07-03 1995-01-12 Basf Ag Wäßrige, mehrphasige, stabile Fertigformulierung für Pflanzenschutz-Wirkstoffe und Verfahren zu ihrer Herstellung
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
US5530195A (en) 1994-06-10 1996-06-25 Ciba-Geigy Corporation Bacillus thuringiensis gene encoding a toxin active against insects
AUPM969994A0 (en) 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
TW334436B (en) 1995-07-21 1998-06-21 Upjohn Co Antiparasitic marcfortines and paraherquamides
FR2739255B1 (fr) 1995-09-29 1998-09-04 Rhone Merieux Composition antiparasitaire pour le traitement et la protection des animaux de compagnie
US5885607A (en) 1996-03-29 1999-03-23 Rhone Merieux N-phenylpyrazole-based anti-flea and anti-tick external device for cats and dogs
US6010710A (en) 1996-03-29 2000-01-04 Merial Direct pour-on skin solution for antiparasitic use in cattle and sheep
IE80657B1 (en) 1996-03-29 1998-11-04 Merial Sas Insecticidal combination to control mammal fleas in particular fleas on cats and dogs
FR2752525B1 (fr) 1996-08-20 2000-05-05 Rhone Merieux Procede de lutte contre les myiases des cheptels bovins et ovins et compositions pour la mise en oeuvre de ce procede
DE19613334A1 (de) 1996-04-03 1997-10-09 Bayer Ag Mittel zur Bekämpfung parasitierender Insekten und Milben an Menschen
US5773704A (en) 1996-04-29 1998-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Herbicide resistant rice
PL191812B1 (pl) 1996-07-17 2006-07-31 Univ Michigan State Materiał roślinny z buraka cukrowego składający się ze zmutowanych komórek, sposób wytwarzania oporności na herbicyd w buraku cukrowym, sposób uzyskiwania oporności na herbicyd w buraku, sposób zwalczania chwastów rosnących razem z burakami cukrowymi
US5773702A (en) 1996-07-17 1998-06-30 Board Of Trustees Operating Michigan State University Imidazolinone herbicide resistant sugar beet plants
FR2753377B1 (fr) 1996-09-19 1999-09-24 Rhone Merieux Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides
US6426333B1 (en) 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
US6998131B2 (en) 1996-09-19 2006-02-14 Merial Limited Spot-on formulations for combating parasites
US6207647B1 (en) 1997-07-18 2001-03-27 Smithkline Beecham Corporation RatA
ES2359973T3 (es) 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
US6348643B1 (en) 1998-10-29 2002-02-19 American Cyanamid Company DNA sequences encoding the arabidopsis acetohydroxy-acid synthase small subunit and methods of use
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
PE20011289A1 (es) 2000-04-07 2001-12-21 Upjohn Co Composiciones antihelminticas que comprenden lactonas macrociclicas y espirodioxepinoindoles
CA2407396C (fr) 2000-04-28 2013-12-31 Basf Aktiengesellschaft Utilisation du gene ahas 2 du mutant x112 du mais et d'herbicides a base d'imidazolinone pour la selection des monocotyledons transgeniques
US6399786B1 (en) 2000-07-14 2002-06-04 Merck & Co., Inc. Nonacyclic nodulisporic acid derivatives
CA2419029A1 (fr) 2000-08-25 2002-02-28 Syngenta Participations Ag Proteine hybrides cristalline du bacillus thuringiensis
TWI223979B (en) 2001-05-09 2004-11-21 Sumitomo Chemical Co Malononitrile compounds and pesticide composition containing the same as well as pest controlling method
EP1414975B1 (fr) 2001-08-09 2016-04-20 University Of Saskatchewan Plants de ble presentant une resistance accrue aux herbicides a base d'imidazolinone
WO2003014356A1 (fr) 2001-08-09 2003-02-20 University Of Saskatchewan Plants de ble presentant une resistance accrue aux herbicides a base d'imidazolinone
AU2002320377B8 (en) 2001-08-09 2008-09-04 Northwest Plant Breeding Company Wheat plants having increased resistance to imidazolinone herbicides
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
AR037856A1 (es) 2001-12-17 2004-12-09 Syngenta Participations Ag Evento de maiz
US7001889B2 (en) 2002-06-21 2006-02-21 Merial Limited Anthelmintic oral homogeneous veterinary pastes
EP1551218B1 (fr) 2002-07-10 2017-05-17 The Department of Agriculture, Western Australia Plants de ble presentant une resistance accrue a un herbicide a base d'imidazolinone
ATE345683T1 (de) 2002-07-17 2006-12-15 Sumitomo Chemical Co Malonsäuerenitril-verbindungen und ihre verwendung als pestizide
US20040151759A1 (en) 2002-08-16 2004-08-05 Douglas Cleverly Non-animal product containing veterinary formulations
TW200409760A (en) 2002-09-11 2004-06-16 Novartis Ag Organic compounds
US9382526B2 (en) 2003-05-28 2016-07-05 Basf Aktiengesellschaft Wheat plants having increased tolerance to imidazolinone herbicides
TWI366442B (en) 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
AR047107A1 (es) 2003-08-29 2006-01-11 Inst Nac De Tecnologia Agropec Plantas de arroz que tienen una mayor tolerancia a los herbicidas de imidazolinona
ATE530517T1 (de) 2003-12-26 2011-11-15 Sumitomo Chemical Co Nitrilverbindung und deren verwendung bei der schädlingsbekämpfung
CN101544606B (zh) 2004-01-16 2012-02-29 住友化学株式会社 丙二腈化合物及其用途
CN1910156B (zh) 2004-01-16 2011-08-17 住友化学株式会社 作为杀虫剂的丙二腈化合物
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
JP2006131529A (ja) 2004-11-05 2006-05-25 Sumitomo Chemical Co Ltd 有害生物防除組成物
JP5051340B2 (ja) * 2005-06-06 2012-10-17 日産化学工業株式会社 置換イソキサゾリン化合物及び有害生物防除剤
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
BRPI0617076B1 (pt) 2005-09-02 2021-07-06 Nissan Chemical Corporation Composto benzamida substituída por isoxazolina da fórmula (1) ou sal do mesmo; composto benzamida substituido por 4-hidroxiiminametila da fórmula (2) ou sal do mesmo; pesticida; agente agroquímico; parasiticida interno ou externo para mamíferos ou aves; inseticida ou acaricida
EP2251336A1 (fr) 2005-10-14 2010-11-17 Sumitomo Chemical Company, Limited Composés de type hydrazide en tant qu' intermédiaires de pesticides
CN103121962B (zh) 2005-11-22 2014-11-12 住友化学株式会社 有机硫化合物及其作为节肢动物杀灭剂的应用
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
JP2009519937A (ja) 2005-12-14 2009-05-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 無脊椎有害生物防除用イソオキサゾリン
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) * 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
DE102006015197A1 (de) 2006-03-06 2007-09-13 Bayer Cropscience Ag Wirkstoffkombination mit insektiziden Eigenschaften
DE102006015467A1 (de) 2006-03-31 2007-10-04 Bayer Cropscience Ag Substituierte Enaminocarbonylverbindungen
KR20090005201A (ko) 2006-04-20 2009-01-12 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충 방제용 피라졸린
JP2008044880A (ja) 2006-08-15 2008-02-28 Bayer Cropscience Ag 殺虫性イソオキサゾリン類
ATE539080T1 (de) 2006-11-30 2012-01-15 Meiji Seika Pharma Co Ltd Schädlingsbekämpfungsmittel
JP5449669B2 (ja) 2006-12-14 2014-03-19 石原産業株式会社 有害生物防除組成物
JP2009001541A (ja) 2006-12-15 2009-01-08 Ishihara Sangyo Kaisha Ltd 新規ピラゾール化合物を中間体として用いるアントラニルアミド系化合物の製造方法
CA2678542C (fr) 2007-03-08 2016-06-07 Meiji Seika Kaisha, Ltd. Composition de controle de ravageurs comportant un derive de pyripyropene
JP5256753B2 (ja) 2007-03-29 2013-08-07 住友化学株式会社 イソオキサゾリン化合物とその有害生物防除用途
JP2008115155A (ja) 2007-04-06 2008-05-22 Nippon Soda Co Ltd 有害生物防除剤組成物及び有害生物防除方法
EP2181100A2 (fr) 2007-04-10 2010-05-05 Bayer CropScience AG Dérivés d'arzlisoxayoline insecticides
EP2155699B9 (fr) 2007-05-15 2016-09-14 Merial, Inc. Composés d'aryloazol-2-yl-cyanoéthylamino, leur procédé de fabrication et leur procédé d'utilisation
BRPI0809770B8 (pt) 2007-06-13 2022-12-06 Du Pont Composto e composição para controlar uma praga de invertebrados
EP2166970B1 (fr) 2007-06-22 2016-09-21 Epix Orthopaedics, Inc. Tige intramédullaire avec pièce de fixation pivotante
EP2455755A3 (fr) 2007-06-22 2012-08-15 GENERA ISTRAZIVANJA d.o.o. Proteoglycan-4 en tant que marqueur pour une insuffisance rénale chronique
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
PL2957284T3 (pl) 2007-06-27 2018-08-31 E. I. Du Pont De Nemours And Company Sposób zwalczania szkodników zwierzęcych
US8053452B2 (en) * 2007-06-29 2011-11-08 Nissan Chemical Industries, Ltd. Substituted isoxazoline or enone oxime compound, and pest control agent
NZ581859A (en) 2007-06-29 2012-06-29 Pfizer Anthelmintic combination comprising 2-desoxoparaherquamide and abamectin
TWI649303B (zh) 2007-08-17 2019-02-01 杜邦股份有限公司 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
MX2010003557A (es) 2007-10-03 2010-04-12 Du Pont Compuestos de isoxazolina de naftaleno para el control de plagas de invertebrados.
WO2009051956A2 (fr) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Insecticides isoxazoline substitué par un pyrazole
DE102008010361A1 (de) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen
TWI518076B (zh) 2008-04-09 2016-01-21 杜邦股份有限公司 製備雜環化合物之方法
BRPI0915665B1 (pt) 2008-07-09 2018-01-02 Basf Se Misturas pesticidas, métodos para proteger plantas do ataque ou infestação por insetos, acarídeos ou nematódeos, para controlar insetos, aracnídeos ou nematódeos, uso de uma mistura, e, composição pesticida ou parasiticida
US9820977B2 (en) 2008-10-03 2017-11-21 Bayer Healthcare Llc Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent
KR101782311B1 (ko) 2008-10-21 2017-09-27 메리얼 인코포레이티드 티오아미드 화합물, 이의 제조 방법 및 사용 방법
CA2747060A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Derives isoxazolines et leur utilisation en tant que pesticide
CN102256971B (zh) * 2008-12-19 2014-09-17 诺华股份有限公司 作为杀虫剂的异噁唑啉衍生物及其用途
DK2513104T3 (en) * 2009-12-17 2016-04-11 Merial Inc ANTIPARASITE DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPREHENSIVE THESE
US20140206633A1 (en) 2010-02-25 2014-07-24 Syngenta Crop Protection Llc Process for the preparation of isoxazoline derivatives
ES2566402T3 (es) 2010-05-27 2016-04-12 E. I. Du Pont De Nemours And Company Forma cristalina de 4-[5-[3-cloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-N-[2-oxo-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenocarboxamida
WO2011154433A2 (fr) 2010-06-09 2011-12-15 Syngenta Participations Ag Mélanges pesticides comprenant des dérivés d' isoxazoline
UY33403A (es) * 2010-06-17 2011-12-30 Novartis Ag Compuestos orgánicos con novedosas isoxazolinas, sus n-óxidos, s-óxidos y sales
DK178277B1 (da) * 2010-06-18 2015-10-26 Novartis Tiergesundheit Ag Diaryloxazolinforbindelser til bekæmpelse af fiskelus
RU2551354C2 (ru) * 2010-08-05 2015-05-20 Зоетис ЭлЭлСи Производные изоксазолина в качестве противопаразитарных агентов
JP2014500282A (ja) * 2010-12-20 2014-01-09 ビーエーエスエフ ソシエタス・ヨーロピア ピラゾール化合物を含む殺有害生物性活性混合物
CN103260620A (zh) 2010-12-27 2013-08-21 英特维特国际股份有限公司 包含三缩四乙二醇的外用局部异噁唑啉制剂
JP2014505089A (ja) * 2011-02-10 2014-02-27 ノバルティス アーゲー 無脊椎有害動物を防除するためのイソオキサゾリン誘導体
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
AU2012224521B2 (en) * 2011-03-10 2015-10-29 Novartis Tiergesundheit Ag Isoxazole derivatives
RS58417B1 (sr) * 2011-09-12 2019-04-30 Merial Inc Paraziticidne kompozicije koje sadrže izoksazolinsko aktivno sredstvo, postupci i upotrebe povezane sa njima
JP6075563B2 (ja) 2011-11-08 2017-02-08 日産化学工業株式会社 光学活性イソキサゾリン化合物の触媒的不斉合成方法及び光学活性イソキサゾリン化合物
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AU2012344083A1 (en) 2011-11-29 2014-05-29 Novartis Tiergesundheit Ag Aryl derivatives for controlling ectoparasites
MX2014009388A (es) 2012-02-03 2014-08-27 Zoetis Llc Procedimiento para la preparacion de derivados de isoxazolina azetidina quirales como agentes antiparasitarios.
RS61949B1 (sr) * 2012-02-06 2021-07-30 Boehringer Ingelheim Animal Health Usa Inc Paraziticidne oralne veterinarske kompozicije koje sadrže sistemski delujuća aktivna sredstva, metodi i primene istih
WO2013150055A1 (fr) 2012-04-04 2013-10-10 Intervet International B.V. Compositions pharmaceutiques orales solides pour des composés d'isoxazoline
JP2014040412A (ja) * 2012-07-27 2014-03-06 Sumitomo Chemical Co Ltd 有害生物防除組成物
AU2013312882B2 (en) * 2012-09-07 2015-11-05 Zoetis Services Llc Spirocyclic isoxazoline parasiticidal combinations
CA2882546A1 (fr) 2012-09-07 2014-03-13 Zoetis Llc Isoxazolines spirocycliques comme agents antiparasitaires
AU2013245478A1 (en) 2012-11-01 2014-05-15 Sumitomo Chemical Company, Limited Method for administering agent for controlling ectoparasite to dog
WO2014081800A1 (fr) 2012-11-21 2014-05-30 Zoetis Llc Synthèse de dérivés d'isoxazoline spirocyclique
WO2014090918A1 (fr) 2012-12-13 2014-06-19 Novartis Ag Procédé pour l'enrichissement énantiomérique de dérivés de diaryloxazoline
TW201522307A (zh) * 2013-03-14 2015-06-16 百靈佳殷格翰國際股份有限公司 經取代２－氮雜－雙環［２．２．１］庚烷－３－羧酸（苄基－氰基－甲基）－醯胺組織蛋白酶ｃ抑制劑
AR096346A1 (es) 2013-05-20 2015-12-23 Zoetis Llc Composiciones antiparasitarias de espiro-isoxazolina de acción prolongada
WO2015048371A1 (fr) * 2013-09-30 2015-04-02 Zoetis Llc Formulations de spiro-isoxazoline à action prolongée
US9371293B2 (en) 2013-10-25 2016-06-21 Sumitomo Chemical Company, Limited Isoxazoline compound composition
PL3063144T3 (pl) * 2013-11-01 2022-01-31 Boehringer Ingelheim Animal Health USA Inc. Przeciwpasożytnicze i szkodniczobójcze związki izoksazolinowe
AU2015343387A1 (en) 2014-11-03 2017-05-18 Zoetis Services Llc Palatable chewable veterinary composition
JP2016145160A (ja) * 2015-02-06 2016-08-12 住友化学株式会社 外部寄生虫防除剤
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
US20170020848A1 (en) * 2015-04-08 2017-01-26 Merial Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
HUE059228T2 (hu) 2015-06-23 2022-10-28 Intervet Int Bv E vitamint tartalmazó izoxazolin oldat, fertõtlenített ivóvízzel való felhasználásra
UY37137A (es) * 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022089B2 (en) * 2004-03-05 2011-09-20 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Patani et al. (Chem. Rev. 1996, 3147-3176) *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018194144A1 (fr) * 2017-04-19 2018-10-25 三井化学アグロ株式会社 Composition de conservation du bois et procédé de traitement de conservation du bois
WO2019091936A1 (fr) 2017-11-07 2019-05-16 Intervet International B.V. Compositions pharmaceutiques à base d'isoxazoline injectables et leur utilisation contre l'infestation par des parasites
EP4316522A2 (fr) 2017-11-07 2024-02-07 Intervet International B.V. Compositions pharmaceutiques d'isoxazoline injectables et leur utilisation contre l'infestation par des parasites
US11858904B2 (en) 2017-11-07 2024-01-02 Intervet Inc. Process for preparing large size isoxazoline particles
EP3723739A4 (fr) * 2017-12-15 2022-04-20 Tarsus Pharmaceuticals, Inc. Préparations de parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite
US11197847B2 (en) 2017-12-15 2021-12-14 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US10835517B2 (en) * 2017-12-15 2020-11-17 Tarsus Pharmaceuticals, Inc. Methods for treating ocular demodex using isoxazoline parasiticide formulations
AU2018385766B2 (en) * 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US11690826B2 (en) 2017-12-15 2023-07-04 Tarsus Pharmaceuticals, Inc. Methods for treating demodex blepharitis using lotilaner formulations
US11690827B2 (en) 2017-12-15 2023-07-04 Tarsus Pharmaceuticals, Inc. Methods for treating ocular Demodex using lotilaner formulations
US11752137B2 (en) 2017-12-15 2023-09-12 Tarsus Pharmaceuticals, Inc. Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
IL275339B1 (en) * 2017-12-15 2023-11-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
CN111655241A (zh) * 2017-12-15 2020-09-11 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
IL275339B2 (en) * 2017-12-15 2024-03-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
WO2020225143A1 (fr) 2019-05-03 2020-11-12 Intervet International B.V. Compositions pharmaceutiques injectables et leurs utilisations
WO2021122515A1 (fr) * 2019-12-16 2021-06-24 Intervet International B.V. Lutte contre les parasites chez les ruminants
WO2021233967A1 (fr) 2020-05-20 2021-11-25 Intervet International B.V. Compositions pharmaceutiques injectables et leurs utilisations

Also Published As

Publication number Publication date
LT3419424T (lt) 2021-07-26
ZA201805476B (en) 2019-06-26
IL282656B (en) 2022-04-01
CN109068651A (zh) 2018-12-21
EP3763211A1 (fr) 2021-01-13
WO2017147352A1 (fr) 2017-08-31
MX2018010160A (es) 2018-11-09
IL261197A (en) 2018-10-31
SG11201806980TA (en) 2018-09-27
AU2017223828B2 (en) 2019-09-26
BR112018017265A2 (pt) 2019-01-15
AU2019236686A1 (en) 2019-10-17
TWI738731B (zh) 2021-09-11
AU2019236686B2 (en) 2021-01-28
JP2019514842A (ja) 2019-06-06
ES2892078T3 (es) 2022-02-02
IL261197B (en) 2021-05-31
UY37137A (es) 2017-09-29
DK3419424T3 (da) 2021-06-28
US20200038370A1 (en) 2020-02-06
BR112018017265B1 (pt) 2023-04-25
TWI827503B (zh) 2023-12-21
HK1257959A1 (zh) 2019-11-01
CL2018002402A1 (es) 2018-10-12
KR20180113614A (ko) 2018-10-16
PT3419424T (pt) 2021-07-02
HRP20211042T1 (hr) 2021-10-01
JP2022163053A (ja) 2022-10-25
SG10202007581QA (en) 2020-09-29
EP3419424B1 (fr) 2021-04-28
JP7110106B2 (ja) 2022-08-01
CO2018008829A2 (es) 2018-11-30
TW202329948A (zh) 2023-08-01
NZ745859A (en) 2019-11-29
EA036716B1 (ru) 2020-12-11
CY1124287T1 (el) 2022-07-22
MX2022003782A (es) 2022-05-25
US11497732B2 (en) 2022-11-15
TW201803857A (zh) 2018-02-01
AU2021202118B2 (en) 2022-03-17
EP3419424A1 (fr) 2019-01-02
TWI801959B (zh) 2023-05-11
CN114573573A (zh) 2022-06-03
AU2022202034A1 (en) 2022-04-14
CN109068651B (zh) 2022-03-01
PL3419424T3 (pl) 2021-11-08
AU2017223828A1 (en) 2018-09-20
JP7346675B2 (ja) 2023-09-19
EA201891893A1 (ru) 2019-01-31
SI3419424T1 (sl) 2021-09-30
TW202229247A (zh) 2022-08-01
HUE054931T2 (hu) 2021-10-28
IL282656A (en) 2021-06-30
CA3015357A1 (fr) 2017-08-31
AU2021202118A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US11497732B2 (en) Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
KR102427124B1 (ko) 구충성 뎁시펩티드 화합물
US9447084B2 (en) Antiparisitic and pesticidal isoxazoline compounds
JP7289349B2 (ja) 駆虫性複素環式化合物
US11589586B2 (en) Pesticidal and parasiticidal pyrazole-isoxazoline compounds
US10653144B2 (en) Pesticidal and parasiticidal vinyl isoxazoline compounds
RU2798093C2 (ru) Противогельминтные гетероциклические соединения
EA044142B1 (ru) Противопаразитарные изоксазолиновые соединения, инъецируемые композиции длительного действия, содержащие их, способы и применение

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERIAL, INC., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LE HIR DE FALLOIS, LOIC PATRICK;MENG, CHARLES Q.;CADY, SUSAN MANCINI;AND OTHERS;REEL/FRAME:042821/0532

Effective date: 20170315

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

STCC Information on status: application revival

Free format text: WITHDRAWN ABANDONMENT, AWAITING EXAMINER ACTION

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION